# Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

> **NCT02062190** · PHASE2 · COMPLETED · sponsor: **Federal University of Rio Grande do Sul** · enrollment: 19 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** resveratrol

## Key facts

- **NCT ID:** NCT02062190
- **Lead sponsor:** Federal University of Rio Grande do Sul
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-01
- **Final completion:** 2015-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02062190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02062190, "Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02062190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*